Ionis Pharmaceuticals Inc (IONS)
37.31
-0.31
(-0.82%)
USD |
NASDAQ |
May 17, 16:00
37.31
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Research and Development Expense (Annual): 899.62M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 899.62M |
| December 31, 2022 | 833.15M |
| December 31, 2021 | 643.45M |
| December 31, 2020 | 535.08M |
| December 31, 2019 | 465.69M |
| December 31, 2018 | 414.60M |
| December 31, 2017 | 374.64M |
| December 31, 2016 | 344.32M |
| December 31, 2015 | 322.29M |
| December 31, 2014 | 241.75M |
| December 31, 2013 | 184.03M |
| December 31, 2012 | 158.46M |
| December 31, 2011 | 157.40M |
| December 31, 2010 | 145.16M |
| December 31, 2009 | 134.62M |
| Date | Value |
|---|---|
| December 31, 2008 | 106.44M |
| December 31, 2007 | 78.20M |
| December 31, 2006 | 69.41M |
| December 31, 2005 | 82.47M |
| December 31, 2004 | 118.47M |
| December 31, 2003 | 116.96M |
| December 31, 2002 | 124.07M |
| December 31, 2001 | 83.74M |
| December 31, 2000 | 57.01M |
| December 31, 1999 | 66.40M |
| December 31, 1998 | 62.20M |
| December 31, 1997 | 55.90M |
| December 31, 1996 | |
| December 31, 1995 | 33.20M |
| December 31, 1994 | 26.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
465.69M
Minimum
2019
899.62M
Maximum
2023
675.40M
Average
643.45M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Biogen Inc | 2.462B |
| Viking Therapeutics Inc | 63.81M |
| Madrigal Pharmaceuticals Inc | 272.35M |
| Akero Therapeutics Inc | 141.80M |
| 89bio Inc | 122.23M |